New cell therapy trial launches for patients with severe COVID-19

(The Cure Alliance) After a lightening round of proposals and reviews, the FDA has authorized a team of scientist brought together by the non-profit organization, The Cure Alliance, to immediately begin a clinical trial using UC-MSC's (umbilical cord-derived mesenchymal stem cells) to block lung inflammation that is the primary cause of death from COVID-19. The international team is led by Dr. Camillo Ricordi.